Recent news on Levalbuterol Hcl

Sepracor Announces First Quarter 2007 Results  -  Apr 24, 2007
PharmaLive.com (press release),XOPENEX(R) brand levalbuterol HCl Inhalation Solution -- XOPENEX Inhalation Solution is a short-acting beta-agonist indicated for the treatment or

Brovana Inhalation Solution Now Available by Prescription for ...  -  Apr 11, 2007
PharmaLive.com (press release),Sepracor's sales force has marketed XOPENEX brand levalbuterol HCl Inhalation Solution, which is a short-acting beta-agonist indicated for the treatment or

Sepracor Announces Fourth Quarter and Full Year 2006 Results  -  Jan 31, 2007
Business Wire (press release),XOPENEX ® brand levalbuterol HCl Inhalation Solution — XOPENEX Inhalation Solution is a short-acting beta-agonist indicated for the treatment or prevention

Sepracor Announces Third Quarter 2006 Operating Results  Oct 26, 2006
...million, of which revenues from pharmaceutical product sales were $193.4 million ($92.5 million for sales of XOPENEX brand levalbuterol HCl Inhalation Solution ... -Genetic Engineering News (press release), Data for XOPENEX(R) Brand of Levalbuterol Presented at American ...  Oct 24, 2006
...of posters of clinical data from studies of XOPENEX HFA(R) (levalbuterol tartrate) Inhalation Aerosol and XOPENEX(R) (levalbuterol HCl) Inhalation Solution at ... -PipelineReview.com (press release), XOPENEX(R) Brand of Levalbuterol Data to Be Presented at American ...  Oct 18, 2006
SEPR) today announced that clinical data for XOPENEX HFA(R) (levalbuterol tartrate) Inhalation Aerosol and XOPENEX(R) (levalbuterol HCl) Inhalation Solution ... -Genetic Engineering News (press release), PARI's TREK and LC Plus Deliver Sepracor's New COPD Medication  Oct 12, 2006
HFA(R) (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler (MDI); and XOPENEX(R) (levalbuterol HCl) Inhalation Solution. ... -International News Service, PARI's TREK and LC Plus Deliver Sepracor's New COPD Medication  Oct 12, 2006
HFA® (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler (MDI); and XOPENEX® (levalbuterol HCl) Inhalation Solution. ... -Yahoo! News (press release) Sepracor Announces Second Quarter 2006 Operating Results  Jul 21, 2006
XOPENEX(R) brand levalbuterol HCl Inhalation Solution - Marketed through Sepracor's sales force, XOPENEX Inhalation Solution is a short-acting bronchodilator ... -Genetic Engineering News

Sepracor Announces Second Quarter 2006 Operating Results  Jul 21, 2006
XOPENEX(R) brand levalbuterol HCl Inhalation Solution - Marketedthrough Sepracor's sales force, XOPENEX Inhalation Solution is ashort-acting bronchodilator ... -Finanzen.net



Sepracor Announces First Quarter 2006 Results  Apr 25, 2006
XOPENEX(R) brand levalbuterol HCl Inhalation Solution - Indicated for treatment or prevention of bronchospasm in patients with reversible obstructive airway ... - Genetic Engineering News

Sepracor Announces First Quarter 2006 Results  Apr 25, 2006
XOPENEX(R) brand levalbuterol HCl Inhalation Solution - Indicatedfor treatment or prevention of bronchospasm in patients withreversible obstructive airway ... - Finanzen.net



Sepracor Announces Fourth Quarter and Full Year 2005 Results ...  Jan 31, 2006
...of which revenues from Sepracor's pharmaceutical product sales were approximately $302.9 million (XOPENEX(R) brand levalbuterol HCl Inhalation Solution ... - Genetic Engineering News

Sepracor Announces Fourth Quarter and Full Year 2005 Results ...  Jan 31, 2006
XOPENEX(R) brand levalbuterol HCl Inhalation Solution - XOPENEXInhalation Solution revenues increased by 34 percent in 2005 versus2004, reaching $428.5 million ... - Finanzen.net

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional